MyFastRx Review
Best for: Cash-pay patients comfortable with 12-month upfront billing for the lowest compounded-GLP-1 monthly rate.
MyFastRx (myfastrx.com) is a cash-pay compounded-GLP-1 telehealth platform operated by MyFastRx Health LLC, emphasizing 'fast prescription approval' and discounted bundle pricing. Compounded semaglutide is $169/mo standard, with multi-month bundles down to $99/mo (12-month upfront) and a SAVE70 first-month promo at $99. Compounded tirzepatide is $249/mo standard, with bundles to $149/mo (12-month) and a first-month SAVE70 promo at $179. 'All doses same price.' Live-verified 2026-05-15: LegitScript seal (ID 24730 visible in seal URL) and HIPAA-compliant certification displayed; insurance not accepted (cash-pay only). State coverage not enumerated — site references 'licensed U.S. providers' and 'nationwide discreet shipping' without an explicit list. Corporate address, medical director, and named pharmacy partner not disclosed on public pages reviewed.
Medium confidence · Last verified 2026-05-15 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
MyFastRx is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
MyFastRx prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| All doses (monthly standard) | compounded | $169 |
| 12-month bundle (billed upfront) | compounded | $99 |
| All doses (monthly standard) | compounded | $249 |
| 12-month bundle (billed upfront) | compounded | $149 |
✓ Pros
- •Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
- •LegitScript ID (24730) traceable
- •All doses same price (no escalation cost)
- •Promo first-month discount lowers trial barrier
✗ Cons
- •States-served list not disclosed — only 'multiple states' / 'licensed U.S. providers'
- •Corporate address and medical director not published
- •Pharmacy partner not named — only 'state-licensed pharmacies'
- •Cash-pay only (no insurance billing)
- •Bundle savings require large upfront commitment (12 months billed)
Ready to start with MyFastRx?
Starting at $99/month. See current pricing and start your free consultation.
Sources & methodology
Our MyFastRx review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to MyFastRx
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with MyFastRx?
Starting at $99/month. See current pricing and start your free consultation.